Solar GSK213500: A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administer01/25/2021 - 01/24/2024 (PI)
GlaxoSmithKline
Real-world Clinical Insights and Inflammatory Mechanisms of07/01/2021 - 06/30/2022 (PI)
The Miriam Hospital National Institute o